Final Palmetto LCD Grants Conditional Reimbursement for MDxHealth's Prostate Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – The Centers for Medicare & Medicaid Services finalized a coverage policy to begin reimbursing MDxHealth's ConfirmMDx prostate cancer test effective Nov. 3.

Medicare contractor Palmetto GBA issued a draft local coverage decision (LCD) a few months ago proposing to cover the test only when it is performed by doctors enrolled in a MolDx-approved certification and training registry program, or CTR.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.